skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Palifermin (Code C2455)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Palifermin

Definition: A recombinant form of the endogenous human keratinocyte growth factor with cell growth promoting activity. Palifermin acts in the manner similar to the endogenous keratinocyte growth factor that binds to keratinocyte growth factor receptors on the epithelial cell surface in the lining of mouth and gastrointestinal tract. This results in stimulation of epithelial cell proliferation, differentiation and upregulation of cytoprotective mechanisms.

NCI-GLOSS Definition: A form of keratinocyte growth factor (KGF) that is made in the laboratory. KGF stimulates the growth of cells that line the surface of the mouth and intestinal tract. Kepivance is used to prevent and treat oral mucositis (mouth sores) caused by high-dose chemotherapy and radiation therapy in leukemia and lymphoma. It is also being studied in the prevention and treatment of oral mucositis and dysphagia (difficulty swallowing) in other types of cancer. Kepivance is a type of recombinant human keratinocyte growth factor.

Display Name: Palifermin

Label: Palifermin

NCI Thesaurus Code: C2455 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0677829  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Growth Factor, Recombinant Human Keratinocyte
Keratinocyte Growth Factor, Recombinant Human
Recombinant Human Keratinocyte Growth Factor
rhu Keratinocyte Growth Factor

External Source Codes: 
CAS Registry Number 162394-19-6 (see NLM ChemIDplus info)
FDA UNII Code QMS40680K6
PDQ Closed Trial Search ID 42905
PDQ Open Trial Search ID 42905 (check for NCI PDQ open clinical trial info)
UMLS CUI C0677829

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Severe oral mucositis with hematologic malignancies, chemotherapy- and radiotherapy-induced
code C2455
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Recombinant_Human_Keratinocyte_Growth_Factor
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom